---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-162653"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:07:56.101071+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Fulcrum expands board to 9, elects Colin Hill; stockholders elect directors, ratify auditor

## Summary
- Board expanded from 8 to 9; Colin Hill elected Class I director, term expiring at 2026 annual meeting.
- Hill received automatic grant of 60,000 nonqualified stock options at $7.00/share.
- Annual meeting: James Collins, James Geraghty, Alex Sapir elected as Class II directors for 3-year term.
- Stockholders ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2024.

## SEC filing metadata
- accession: 0001193125-24-162653
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312524162653/0001193125-24-162653-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312524162653/d845947d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-162653
- JSON: https://secwatch.observer/filing/0001193125-24-162653.json
- Plain text: https://secwatch.observer/filing/0001193125-24-162653.txt

## Key facts
- Executive change
  Colin Hill was elected as Class I Director at Fulcrum Therapeutics, Inc..
  - Action: elected
  - Role: Class I Director
  source text: elected Colin Hill as a member of the Board, effective June 17, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312524162653/0001193125-24-162653-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.